National Association of Pharmacy Regulatory Authorities
National Association of Pharmacy Regulatory Authorities

Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Reset
Print Friendly Export to CSV
Drug Name Comment Schedule Date
L-TryptophanPDL

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

 I DEC / 13
Labetalol or its saltsPDL I DEC / 13
Lacosamide or its derivativesPDL I DEC / 13
Lactic acidPDL

when recommended for parenteral use as a tissue sclerosing agent

 I DEC / 13
Lactic acid.

in preparations in concentrations of more than 10% except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses

 III DEC / 14
Lactulose III SEP / 98
Lamivudine or its saltsPDL I DEC / 13
Lamotrigine or its saltsPDL I DEC / 13
LanadelumabPDL I NOV / 18
Lanreotide or its saltsPDL I DEC / 13
Lansoprazole and its saltsPDL I DEC / 13
Lanthanum saltsPDL

when sold for the treatment of hyperphosphatemia for human use

 I DEC / 13
Lapatinib or its saltsPDL I DEC / 13
LaronidasePDL I DEC / 13
Ledipasvir or its saltsPDL I DEC / 14
Lefetamine and any Salt thereofC4 I JAN / 03
Leflunomide or its salts or derivativesPDL

including but not limited to teriflunomide 

 I DEC / 13
LenalidomidePDL I DEC / 13
Lenvatinib or its saltsPDL I AUG / 16
Letermovir or its saltsPDL I DEC / 17
LetrozolePDL I DEC / 13
Leucovorin or its saltsPDL I DEC / 13
Leuprolide or its saltsPDL I DEC / 13
Levallorphane and its salts I SEP / 98
Levamisole or its saltsPDL

for human use 

 I DEC / 13
Levargorphane and its salts II SEP / 98
LevetiracetamPDL I DEC / 13
Levobunolol or its saltsPDL I DEC / 13
Levocabastine or its salts or derivativesPDL I DEC / 13
Levocarnitine or its salts or derivativesPDL

when sold for the treatment of primary or secondary levocarnitine deficiency

 I DEC / 13
Levodopa or its saltsPDL I DEC / 13
LevomethorphanN I JUN / 02
Levomilnacipran or its saltsPDL I JUN / 15
LevomoramideN I JUN / 02
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
LevophenacylmorphanN I JUN / 02
LevorphanolN I JUN / 02
LidocainePDL

when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher for human use

 I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

 III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

 U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its saltsPDL I MAR / 18
Linaclotide or its salts or derivativesPDL I DEC / 13
Linagliptin or its salts or derivativesPDL I DEC / 13
Lincomycin or its salts or derivativesPDL

Including but not limited to: Clindamycin 

 I DEC / 18
Lindane II SEP / 98
Linezolid or its saltsPDL I DEC / 13
Liothyronine or its saltsPDL

for human use 

 I DEC / 13
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its saltsPDL I DEC / 13
Lisinopril or its salts or derivativesPDL I DEC / 13
Lithium or its saltsPDL I DEC / 13
Lixisenatide or its saltsPDL I JUN / 17
Lodoxamide or its salts or derivativesPDL

including but not limited to Lodoxamide tromethamine

 I DEC / 13
Lomefloxacin or its saltsPDL I DEC / 13
Lomitapide or its saltsPDL I FEB / 14
LomustinePDL I DEC / 13
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
LopinavirPDL I DEC / 13
LoprazolamTS I JUN / 02
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorazepam and its saltsTS I SEP / 98
Lorlatinib or its salts PDL I MAR / 19
LormetazepamTS I JUN / 02
Losartan or its saltsPDL I DEC / 13
Losoxantrone or its saltsPDL I DEC / 13
LotilanerPDL

For veterinary use

 I MAR / 18
LovastatinPDL

except in oral dosage form that provides 1 milligram (mg) or less per daily dose

 I DEC / 14
Loxapine or its saltsPDL I DEC / 13
Lumacaftor or its salts or derivativesPDL I AUG / 16
LumiracoxibPDL I DEC / 13
Lurasidone or its saltsPDL I DEC / 13
Lutropin alfaPDL I DEC / 13
Lyme Disease vaccine I FEB / 02

79 result(s)

Print Friendly Export to CSV

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled